Fluvastatin mitigates SARS-CoV-2 infection in human lung cells
Summary: Clinical data of patients suffering from COVID-19 indicates that statin therapy, used to treat hypercholesterolemia, is associated with a better disease outcome. Whether statins directly affect virus replication or influence the clinical outcome through modulation of immune responses is unk...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/34bc37bb80fe4e8db30733cdbb761e1b |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:34bc37bb80fe4e8db30733cdbb761e1b |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:34bc37bb80fe4e8db30733cdbb761e1b2021-11-28T04:37:04ZFluvastatin mitigates SARS-CoV-2 infection in human lung cells2589-004210.1016/j.isci.2021.103469https://doaj.org/article/34bc37bb80fe4e8db30733cdbb761e1b2021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2589004221014401https://doaj.org/toc/2589-0042Summary: Clinical data of patients suffering from COVID-19 indicates that statin therapy, used to treat hypercholesterolemia, is associated with a better disease outcome. Whether statins directly affect virus replication or influence the clinical outcome through modulation of immune responses is unknown. We therefore investigated the effect of statins on SARS-CoV-2 infection in human lung cells and found that only fluvastatin inhibited low and high pathogenic coronaviruses in vitro and ex vivo in a dose-dependent manner. Quantitative proteomics revealed that fluvastatin and other tested statins modulated the cholesterol synthesis pathway without altering innate antiviral immune responses in infected lung epithelial cells. However, fluvastatin treatment specifically downregulated proteins that modulate protein translation and viral replication. Collectively, these results support the notion that statin therapy poses no additional risk to individuals exposed to SARS-CoV-2 and that fluvastatin has a moderate beneficial effect on SARS-CoV-2 infection of human lung cells.Francisco J. Zapatero-BelinchónRebecca MoellerLisa LasswitzMarco van HamMiriam BeckerGraham BrogdenEbba RosendalWenjie BiBelén Carriquí-MadroñalKoushikul IslamAnnasara LenmanAntonia P. GuneschJared KiruiThomas PietschmannAnna K. ÖverbyLothar JänschGisa GeroldElsevierarticleDrugsVirologyScienceQENiScience, Vol 24, Iss 12, Pp 103469- (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Drugs Virology Science Q |
| spellingShingle |
Drugs Virology Science Q Francisco J. Zapatero-Belinchón Rebecca Moeller Lisa Lasswitz Marco van Ham Miriam Becker Graham Brogden Ebba Rosendal Wenjie Bi Belén Carriquí-Madroñal Koushikul Islam Annasara Lenman Antonia P. Gunesch Jared Kirui Thomas Pietschmann Anna K. Överby Lothar Jänsch Gisa Gerold Fluvastatin mitigates SARS-CoV-2 infection in human lung cells |
| description |
Summary: Clinical data of patients suffering from COVID-19 indicates that statin therapy, used to treat hypercholesterolemia, is associated with a better disease outcome. Whether statins directly affect virus replication or influence the clinical outcome through modulation of immune responses is unknown. We therefore investigated the effect of statins on SARS-CoV-2 infection in human lung cells and found that only fluvastatin inhibited low and high pathogenic coronaviruses in vitro and ex vivo in a dose-dependent manner. Quantitative proteomics revealed that fluvastatin and other tested statins modulated the cholesterol synthesis pathway without altering innate antiviral immune responses in infected lung epithelial cells. However, fluvastatin treatment specifically downregulated proteins that modulate protein translation and viral replication. Collectively, these results support the notion that statin therapy poses no additional risk to individuals exposed to SARS-CoV-2 and that fluvastatin has a moderate beneficial effect on SARS-CoV-2 infection of human lung cells. |
| format |
article |
| author |
Francisco J. Zapatero-Belinchón Rebecca Moeller Lisa Lasswitz Marco van Ham Miriam Becker Graham Brogden Ebba Rosendal Wenjie Bi Belén Carriquí-Madroñal Koushikul Islam Annasara Lenman Antonia P. Gunesch Jared Kirui Thomas Pietschmann Anna K. Överby Lothar Jänsch Gisa Gerold |
| author_facet |
Francisco J. Zapatero-Belinchón Rebecca Moeller Lisa Lasswitz Marco van Ham Miriam Becker Graham Brogden Ebba Rosendal Wenjie Bi Belén Carriquí-Madroñal Koushikul Islam Annasara Lenman Antonia P. Gunesch Jared Kirui Thomas Pietschmann Anna K. Överby Lothar Jänsch Gisa Gerold |
| author_sort |
Francisco J. Zapatero-Belinchón |
| title |
Fluvastatin mitigates SARS-CoV-2 infection in human lung cells |
| title_short |
Fluvastatin mitigates SARS-CoV-2 infection in human lung cells |
| title_full |
Fluvastatin mitigates SARS-CoV-2 infection in human lung cells |
| title_fullStr |
Fluvastatin mitigates SARS-CoV-2 infection in human lung cells |
| title_full_unstemmed |
Fluvastatin mitigates SARS-CoV-2 infection in human lung cells |
| title_sort |
fluvastatin mitigates sars-cov-2 infection in human lung cells |
| publisher |
Elsevier |
| publishDate |
2021 |
| url |
https://doaj.org/article/34bc37bb80fe4e8db30733cdbb761e1b |
| work_keys_str_mv |
AT franciscojzapaterobelinchon fluvastatinmitigatessarscov2infectioninhumanlungcells AT rebeccamoeller fluvastatinmitigatessarscov2infectioninhumanlungcells AT lisalasswitz fluvastatinmitigatessarscov2infectioninhumanlungcells AT marcovanham fluvastatinmitigatessarscov2infectioninhumanlungcells AT miriambecker fluvastatinmitigatessarscov2infectioninhumanlungcells AT grahambrogden fluvastatinmitigatessarscov2infectioninhumanlungcells AT ebbarosendal fluvastatinmitigatessarscov2infectioninhumanlungcells AT wenjiebi fluvastatinmitigatessarscov2infectioninhumanlungcells AT belencarriquimadronal fluvastatinmitigatessarscov2infectioninhumanlungcells AT koushikulislam fluvastatinmitigatessarscov2infectioninhumanlungcells AT annasaralenman fluvastatinmitigatessarscov2infectioninhumanlungcells AT antoniapgunesch fluvastatinmitigatessarscov2infectioninhumanlungcells AT jaredkirui fluvastatinmitigatessarscov2infectioninhumanlungcells AT thomaspietschmann fluvastatinmitigatessarscov2infectioninhumanlungcells AT annakoverby fluvastatinmitigatessarscov2infectioninhumanlungcells AT lotharjansch fluvastatinmitigatessarscov2infectioninhumanlungcells AT gisagerold fluvastatinmitigatessarscov2infectioninhumanlungcells |
| _version_ |
1718408251464220672 |